Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106691 · ClinicalTrials.gov registry record · Phase 3
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
A Phase 3 study, sponsored by GTx.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,589
- Enrollment target
NCT00106691 is a Phase 3 study that has completed, run by GTx. The registered enrollment target is 1,589 participants.
The verdict
NCT00106691, a Phase 3 study, has completed, sponsored by GTx.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,589 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
Interventions
- DRUG Placebo
- DRUG Toremifene 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,589 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106691
The ClinicalTrials.gov registry entry for NCT00106691 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,589 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00106691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106691 about?
NCT00106691 is a clinical study titled "Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)". The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
What is the current status of trial NCT00106691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,589 participants. The study started on 2005-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00106691?
The interventions under investigation include: Placebo (DRUG), Toremifene 20 mg (DRUG).
Who is sponsoring clinical trial NCT00106691?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.